Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
Br J Dermatol 2023 Mar 30;[EPub Ahead of Print], A Blauvelt, JP Thyssen, E Guttman-Yassky, T Bieber, E Serra-Baldrich, E Simpson, D Rosmarin, H Elmaraghy, E Meskimen, CR Natalie, Z Liu, C Xu, E Pierce, M Morgan-Cox, E Garcia Gil, JI SilverbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.